
Ocular Therapeutix (OCUL) Stock Forecast & Price Target
Ocular Therapeutix (OCUL) Analyst Ratings
Bulls say
Ocular Therapeutix is a biotechnology company with an exciting pipeline of potential eye medication, including Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT. The recent milestone of a streamlined path to approval for OTX-TKI, along with positive data for AXPAXLI in wet AMD, has bolstered confidence in the company's potential. However, like all biotech companies, there are inherent risks associated with investing, including stock price volatility and regulatory and commercial risks. Despite these risks, the strong potential for market success and innovative treatments make Ocular Therapeutix a promising investment opportunity.
Bears say
Ocular Therapeutix is valued at $5.55B and has a Buy rating with a $25 price target. The company's success heavily relies on its lead candidate Axpaxli, which is currently in Phase 3 clinical trials for wet AMD and NPDR. Risks include potential failure in clinical trials or inability to successfully commercialize, as well as potential intellectual property risks and stock price volatility. However, the recent successful Pre-NDA meeting with the FDA for Axpaxli and potential approval in 2027 suggest a promising outlook for the company's pipeline.
This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.
Ocular Therapeutix (OCUL) Analyst Forecast & Price Prediction
Start investing in Ocular Therapeutix (OCUL)
Order type
Buy in
Order amount
Est. shares
0 shares